Join to access to all OVN content. Join for Free
Field Medical Execution Despite Limited Resources
Neurology MSLs managing MSL teams virtual platforms impact engaging KOLs strategies future of MSL role

Field Medical Execution Despite Limited Resources


Share This Article


Summary

In this episode, Ed Cunningham delves into his extensive background in Neurology MSLs and shares insights on managing MSL teams, including the role of outsourcing. He explores the impact of virtual platforms and technology on MSL interactions, and offers strategies for engaging KOLs in the post-COVID landscape. Ed addresses the challenges of maintaining effectiveness in large territories, and discusses metrics for performance measurement in Medical Affairs. The conversation extends to the future of the MSL role, hybrid work models, and the evolving value of MSLs to stakeholders. The episode concludes with closing remarks and sponsorship from Synovian Pharmaceuticals.

My guest today is Ed Cunningham, Executive Director, Neurology MSLs with Sunovian Pharmaceuticals shares insights for Field Medical Execution Despite Limited Resources

Ed discusses…

πŸ‘‰ How to lead MSL teams with limited resources
πŸ‘‰ The importance of outsourcing to support field-based efforts and activities
πŸ‘‰ Virtual and alternative platforms to share data and gather insights
πŸ‘‰ What are best practices for prioritizing KOL engagement and tracking
πŸ‘‰ How budget plays a factor
πŸ‘‰ How an MSL can maintain effectiveness in a very large territory
πŸ‘‰ How an MSL can adapt a territory plan to accomplish objectives

Click for Source
Neurology MSLs, managing MSL teams, virtual platforms impact, engaging KOLs strategies, future of MSL role

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis
OVN Avatar Jayson L. Parker, Sebnem S. Kuzulugil, Kirill Pereverzev, Stephen Mac, Gilberto Lopes, Zain Shah, Ashini Weerasinghe, Daniel Rubinger, Adam Falconi, Ayse Bener, Bora Caglayan, Rohan Tangri, Nicholas Mitsakakis

Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis

Article
Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval
OVN Avatar Avi Cherla, MSc; Huseyin Naci, MHS, PhD; Aaron S. Kesselheim, MD, JD, MPH; Bishal Gyawali, MD, PhD; Elias Mossialos, MD, PhD

Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval

Article
Assessment of Food and Drug Administration- and European Medicines Agency-Approved Systemic Oncology Therapies and Clinically Meaningful Improvements in Quality of Life: A Systematic Review
OVN Avatar Vanessa Arciero, BS, Seanthel Delos Santos, Liza Koshy

Assessment of Food and Drug Administration- and European Medicines Agency-Approved Systemic Oncology Therapies and Clinically Meaningful Improvements in Quality of Life: A Systematic Review

Article
Clinical Educator Oncology Program Improves Adherence by 29%​
Partner Avatar iNIZIO

Clinical Educator Oncology Program Improves Adherence by 29%​

Article
New Book Unites Oncology’s Brightest Minds To Innovate Cancer Cures
OVN Avatar Forbes Books Press Release Official

New Book Unites Oncology’s Brightest Minds To Innovate Cancer Cures

Article
CheckMate-067: Raising the Bar for the Next Decade in Oncology
OVN Avatar Sarah A. Weiss, MD, and Harriet Kluger, MD

CheckMate-067: Raising the Bar for the Next Decade in Oncology

Explore OVN